Zibotentan
 | |
| Names | |
|---|---|
| IUPAC name
N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide | |
| Other names
ZD4054 | |
| Identifiers | |
186497-07-4  | |
| 3D model (Jmol) | Interactive image |
| ChemSpider | 8085875  |
| ECHA InfoCard | 100.171.075 |
| 3539 | |
| PubChem | 9910224 |
| UNII | 8054MM4902 |
| |
| |
| Properties | |
| C19H16N6O4S | |
| Molar mass | 424.44 g·mol−1 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| verify (what is ?) | |
| Infobox references | |
Zibotentan (INN) (earlier code name ZD4054) is an anti-cancer candidate.[1] It is an endothelin receptor antagonist.[2]
It failed a phase III clinical trial for prostate cancer[3] but other trials are planned.[4] Tolerability of zibotentan plus docetaxel has been evaluated.[5]
References
- ↑ James and Growcott (2009). "Drugs of the Future".
- ↑ Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T (2011). "Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies". BMC Clin Pharmacol. 11: 3. doi:10.1186/1472-6904-11-3. PMC 3070638
. PMID 21414193. - ↑ http://www.fiercebiotech.com/story/azs-zibotentan-flunks-late-stage-prostate-cancer-trial/2010-09-27
- ↑ http://www.genengnews.com/gen-news-highlights/pfizer-astrazeneca-and-actelion-separately-report-phase-iii-trial-failures/81243985/
- ↑ Trump DL, Payne H, Miller K, et al. (September 2011). "Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer". Prostate. 71 (12): 1264–75. doi:10.1002/pros.21342. PMID 21271613.
External links
This article is issued from Wikipedia - version of the 6/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.